Cardiff Oncology's Cancer Drug Shines, But Pivotal Test Awaits

SAN DIEGO, CA – February 24, 2026 – Cardiff Oncology has unveiled clinical data that could represent one of the most significant advances in decades for a notoriously difficult-to-treat group of colorectal cancer patients. The company's lead drug candidate, onvansertib, demonstrated a dramatic improvement in patient response rates when added to standard chemotherapy, positioning the small biotech at a critical juncture as it prepares to navigate the costly and complex path toward regulatory approval.

In a business update accompanying its full-year 2025 financial results, the San Diego-based firm reported that its Phase 2 trial, CRDF-004, met its primary goals with impressive results. The study focuses on patients with first-line RAS-mutated metastatic colorectal cancer (mCRC), a large patient population that accounts for roughly half of all mCRC cases and has seen little therapeutic innovation in over twenty years.

A Breakthrough in a Stubborn Cancer

The data from the trial's most successful arm showed a striking difference in efficacy. Patients receiving 30 mg of onvansertib in combination with a standard chemotherapy regimen (FOLFIRI/bev) achieved a confirmed objective response rate (ORR) of 72.2%. This figure, which measures tumor shrinkage, stands in sharp contrast to the 43.2% ORR seen in patients who received the standard of care alone.

“Our focus in 2025 was on rigorous clinical execution, which allowed us to generate increasingly compelling evidence supporting onvansertib’s potential to improve patient outcomes in RAS-mutated mCRC,” said Mani Mohindru, PhD, who recently stepped in as interim Chief Executive Officer. “Given that it has been over two decades since there has been meaningful innovation for this patient population, we believe these results represent a transformative step forward.”

Beyond just shrinking tumors, the combination therapy also appeared to keep the cancer at bay for longer. The company reported a significant improvement in progression-free survival (PFS), with a hazard ratio of 0.37, indicating a 63% reduction in the risk of disease progression or death compared to the standard of care. Crucially, these benefits were achieved without adding significant toxicity, a key concern when adding new agents to intensive chemotherapy backbones.

Onvansertib works by inhibiting PLK1, a protein that plays a critical role in cell division. Cancer cells, particularly those with RAS mutations, are often highly dependent on PLK1 to manage the stress of their rapid, uncontrolled proliferation. By blocking PLK1, onvansertib is believed to push these vulnerable cancer cells into a state of mitotic catastrophe, leading to cell death. The strength of the new data provides powerful clinical validation for this scientific approach.

A Company in Transition

While the clinical news is overwhelmingly positive, it arrives during a period of significant transition for Cardiff Oncology. In January, the company announced a major leadership shake-up, with both its Chief Executive Officer and Chief Financial Officer stepping down. The board appointed Dr. Mohindru, a director since 2021 with deep experience in biotech corporate strategy, as interim CEO to steer the company into its next phase.

The official rationale for the change was to align leadership with the company's pivot toward late-stage development and eventual commercialization. However, the simultaneous departure of two top executives at such a critical moment has drawn scrutiny from industry observers. The company is now tasked with finding permanent leadership while simultaneously planning for its most ambitious and expensive clinical program to date.

Financially, Cardiff Oncology ended 2025 with approximately $58.3 million in cash and equivalents. The company projects this provides a cash runway into the first quarter of 2027. While this offers a near-term cushion, the cost of a large, global registrational (Phase 3) trial required for FDA approval can run into the hundreds of millions of dollars. The company will almost certainly need to raise significant additional capital to bring onvansertib to market.

“Based on these results, we plan to advance the 30 mg dose of onvansertib with FOLFIRI/bev into our proposed registrational program,” Dr. Mohindru stated, confirming the company's next steps. The immediate priority is a series of crucial discussions with the U.S. Food and Drug Administration (FDA) to finalize the design of this pivotal trial. The company expects to unveil detailed plans in the first half of 2026, a milestone that will be closely watched by investors and the medical community.

Beyond Colorectal Cancer

The promise of onvansertib may extend beyond the gastrointestinal tract. Cardiff also highlighted preliminary data from a separate investigator-sponsored trial in chronic myelomonocytic leukemia (CMML), a rare and aggressive blood cancer. In that small Phase 1 study, onvansertib monotherapy was generally well-tolerated and showed signs of clinical activity in about 40% of patients. While early, these findings help validate the broader potential of PLK1 inhibition as a therapeutic strategy across both solid tumors and hematologic malignancies.

This multi-indication potential is a key aspect of the drug's long-term value proposition. As the company focuses its resources on the most immediate opportunity in colorectal cancer, these other signals provide a glimpse into a potentially wider future for onvansertib and the PLK1 inhibitor class.

For now, all eyes are on the path forward in mCRC. After two decades of frustratingly incremental progress, the results from the CRDF-004 trial have ignited hope for a meaningful change in the standard of care. Cardiff Oncology has a promising drug, a clear development path, and a patient population in desperate need of new options. Its success now hinges on flawless execution through the demanding gauntlet of late-stage clinical trials, regulatory negotiations, and the financial pressures of biotech innovation.